Here, we evaluated RNA and DNA-based determinants of response to preoperative HER3-DXd in patients with newly diagnosed HR+/HER2- breast cancer using samples from the SOLTI-1805 TOT-HER3 trial27. This evidence concerns the gene ERBB3 and breast carcinoma.